Remdesivir maleate
Based on 226 publication(s) in Google Scholar
Remdesivir maleate (GS-5734 maleate) is a nucleoside analogue with effective antiviral activity. Remdesivir maleate can inhibit the synthesis of viral DNA or RNA. Remdesivir maleate can be used for the research of infection, such as SARS-CoV and MHV infection.
For research use only. We do not sell to patients.
- CAS No.: 2250110-53-1
- Formula: C31H39N6O12P
- Molecular Weight:718.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Remdesivir maleate
More- N Engl J Med. 2023 Jan 5;388(1):89-91. [Abstract]
- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Signal Transduct Target Ther. 2021 Apr 24;6(1):165. [Abstract]
- Signal Transduct Target Ther. 2021 Feb 4;6(1):51. [Abstract]
- Nature. 2021 May;593(7859):418-423. [Abstract]
- Nature. 2020 Jun;582(7813):561-565. [Abstract]
- Science. 2021 Nov 26;374(6571):1099-1106. [Abstract]
- Science. 2020 Jun 26;368(6498):1499-1504. [Abstract]
- Cell Res. 2020 Mar;30(3):269-271. [Abstract]
- Nat Cell Biol. 2023 Aug;25(8):1223-1234. [Abstract]
- J Extracell Vesicles. 2022 Jan;11(1):e12179. [Abstract]
- Sci Bull. 2021 May 15;66(9):925-936. [Abstract]
- Nat Microbiol. 2024 May;9(5):1189-1206. [Abstract]
- Nat Commun. 2026 Mar 17;17(1):4058. [Abstract]
- Nat Commun. 2023 Jul 15;14(1):4231. [Abstract]
- Nat Commun. 2023 Jul 4;14(1):3952. [Abstract]
- Nat Commun. 2021 Nov 5;12(1):6415. [Abstract]
- Nat Commun. 2021 Oct 4;12(1):5811. [Abstract]
- Nat Commun. 2021 Aug 9;12(1):4887. [Abstract]
- Cell Discov. 2022 Sep 9;8(1):89. [Abstract]
- Redox Biol. 2021 Sep:45:102041. [Abstract]
- Sci Transl Med. 2023 Jan 18;15(679):eabq4064. [Abstract]
- Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. [Abstract]
- Acta Pharm Sin B. 2026 Jul;16(7):4410-4425. [Abstract]
- Acta Pharm Sin B. 2024 Sep;14(9):4028-4044. [Abstract]
- Acta Pharm Sin B. 2021 Sep;11(9):2850-2858. [Abstract]
- MedComm (2020). 2025 Aug 31;6(9):e70353. [Abstract]
- Cell Rep Med. 2026 Mar 9:102646. [Abstract]
- Biomaterials. 2024 Dec:311:122689. [Abstract]
- Biomaterials. 2022 Apr:283:121460. [Abstract]
- J Control Release. 2025 Jan 22:379:558-573. [Abstract]
- Int J Biol Sci. 2020 Oct 16;16(16):3100-3115. [Abstract]
- EBioMedicine. 2022 Jul:81:104132. [Abstract]
- Arch Toxicol. 2022 Aug;96(8):2341-2360. [Abstract]
- Acta Pharmacol Sin. 2025 Jul;46(7):2006-2015. [Abstract]
- Cell Chem Biol. 2022 Jul 21;29(7):1113-1125.e6. [Abstract]
- Int J Nanomedicine. 2023 Mar 27:18:1561-1575. [Abstract]
- Int J Biol Macromol. 2021 Jan 31:168:474-485. [Abstract]
- Microbiol Res. 2024 Aug:285:127750. [Abstract]
- Phytother Res. 2025 Mar 18. [Abstract]
- Cell Rep. 2024 Nov 5;43(11):114929. [Abstract]
- Cell Rep. 2021 Nov 23;37(8):110049. [Abstract]
- Cell Rep. 2021 Apr 6;35(1):108959. [Abstract]
- Genes Dev. 2021 Jul 1;35(13-14):1005-1019. [Abstract]
- J Med Chem. 2025 Sep 25;68(18):19076-19106. [Abstract]
- J Med Chem. 2024 May 9;67(9):7470-7486. [Abstract]
- Emerg Microbes Infect. 2024 Dec;13(1):2368217. [Abstract]
- Fundam Res. 2023 Apr 7;5(6):2975-2982. [Abstract]
- Emerg Microbes Infect. 2021 Dec;10(1):291-304. [Abstract]
- Emerg Microbes Infect. 2021 Dec;10(1):317-330. [Abstract]
- Pharmaceutics. 2024 Sep 27;16(10):1262. [Abstract]
- Pharmaceutics. 2021 Oct 11;13(10):1656. [Abstract]
- J Ethnopharmacol. 2025 Aug 29:352:120249. [Abstract]
- J Ethnopharmacol. 2024 Oct 28:333:118490. [Abstract]
- Eur J Med Chem. 2021 Nov 15:224:113683. [Abstract]
- Mol Syst Biol. 2021 Feb;17(2):e10188. [Abstract]
- Cell Biosci. 2024 Sep 6;14(1):115. [Abstract]
- Biomed J. 2021 Jun;44(3):293-303. [Abstract]
- Biosensors (Basel). 2022 Nov 1;12(11):950. [Abstract]
- Bioeng Transl Med. 2020 Dec 1;6(1):e10196. [Abstract]
- J Cell Biol. 2025 Mar 3;224(3):e202306101. [Abstract]
- J Neuroimmune Pharmacol. 2024 May 21;19(1):22. [Abstract]
- Front Drug Discov. 2023 Jan 5.
- Commun Biol. 2022 Feb 22;5(1):154. [Abstract]
- Eur J Pharmacol. 2025 Jun 5:996:177537. [Abstract]
- Pharmaceuticals (Basel). 2020 Apr 10;13(4):65. [Abstract]
- Int J Mol Sci. 2026 Apr 21;27(8):3685. [Abstract]
- Stem Cell Reports. 2023 Jun 13;18(6):1308-1324. [Abstract]
- Biomolecules. 2021 Dec 10;11(12):1858. [Abstract]
- Int J Mol Sci. 2021 Jan 30;22(3):1398. [Abstract]
- Front Cell Infect Microbiol. 2021 Jul 30:11:700502. [Abstract]
- mBio. 2023 Aug 31;14(4):e0106023. [Abstract]
- mBio. 2023 Apr 25;14(2):e0328522. [Abstract]
- Front Pharmacol. 2020 Jul 21;11:1091. [Abstract]
- ACS Omega. 2026 Apr 30;11(18):26533-26543. [Abstract]
- ACS Omega. 2026 Jan 26;11(5):8667-8677. [Abstract]
- Molecules. 2022 Dec 12;27(24):8829. [Abstract]
- Molecules. 2020 May 17;25(10):2343. [Abstract]
- Sci Rep. 2026 Mar 9. [Abstract]
- Sci Rep. 2025 Nov 27. [Abstract]
- Sci Rep. 2025 Aug 2;15(1):28197. [Abstract]
- Sci Rep. 2025 Aug 22;15(1):30935. [Abstract]
- Sci Rep. 2025 May 26;15(1):18443. [Abstract]
- Sci Rep. 2023 Nov 17;13(1):20178. [Abstract]
- Sci Rep. 2021 Dec 6;11(1):23465. [Abstract]
- PLoS Pathog. 2021 Sep 17;17(9):e1009929. [Abstract]
- Sci Rep. 2021 Mar 8;11(1):5376. [Abstract]
- Sci Rep. 2021 Mar 8;11(1):5433. [Abstract]
- Sci Rep. 2021 Jan 12;11(1):821. [Abstract]
- Sci Rep. 2020 Oct 1;10(1):16200. [Abstract]
- Comput Struct Biotechnol J. 2022:20:5193-5202. [Abstract]
- Virol Sin. 2025 Mar 25:S1995-820X(25)00031-8. [Abstract]
- Virol Sin. 2023 Oct;38(5):778-786. [Abstract]
- Microorganisms. 2021 Aug 14;9(8):1731. [Abstract]
- Microorganisms. 2021 Mar 31;9(4):734. [Abstract]
- Microorganisms. 2020 Nov 26;8(12):1872. [Abstract]
- Int J Infect Dis. 2024 Sep:146:107134. [Abstract]
- ACS Infect Dis. 2025 Jun 13;11(6):1518-1527. [Abstract]
- iScience. 2021 Dec 17;24(12):103412. [Abstract]
- Biomedicines. 2021 Nov 19;9(11):1725. [Abstract]
- iScience. 2021 Oct 22;24(10):103120. [Abstract]
- Biomedicines. 2021 Aug 11;9(8):996. [Abstract]
- J Neural Transm (Vienna). 2021 Jul;128(7):1159-1168. [Abstract]
- Antiviral Res. 2026 Jun:250:106413. [Abstract]
- Antiviral Res. 2025 Dec:244:106309. [Abstract]
- Antiviral Res. 2025 Oct:242:106263. [Abstract]
- Antiviral Res. 2025 Apr:236:106114. [Abstract]
- Antiviral Res. 2024 May:225:105856. [Abstract]
- Antiviral Res. 2023 Sep:217:105700. [Abstract]
- Antiviral Res. 2023 Aug:216:105671. [Abstract]
- Antiviral Res. 2023 Jun:214:105619. [Abstract]
- Antiviral Res. 2023 Jun:214:105606. [Abstract]
- Antiviral Res. 2022 Aug:204:105365. [Abstract]
- Clin Transl Sci. 2022 Mar;15(3):732-740. [Abstract]
- Clin Transl Sci. 2022 Feb;15(2):501-513. [Abstract]
- Mol Divers. 2021 Aug;25(3):1839-1854. [Abstract]
- Antiviral Res. 2021 Jul:191:105089. [Abstract]
- Antiviral Res. 2021 Jan:185:104977. [Abstract]
- Antiviral Res. 2020 Dec:184:104955. [Abstract]
- Antiviral Res. 2020 Jun:178:104786. [Abstract]
- Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0103924. [Abstract]
- Antimicrob Agents Chemother. 2024 Jun 5;68(6):e0034124. [Abstract]
- Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0170322. [Abstract]
- Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00819-20. [Abstract]
- Microbiol Spectr. 2026 May 15:e0309325. [Abstract]
- J Virol. 2024 Feb 20;98(2):e0121623. [Abstract]
- J Antimicrob Chemother. 2023 Apr 3;78(4):946-952. [Abstract]
- J Virol. 2021 Sep 27;95(20):e0064321. [Abstract]
- Virol J. 2025 Mar 4;22(1):56. [Abstract]
- Virol J. 2023 Jan 31;20(1):18. [Abstract]
- mSphere. 2021 May 5;6(3):e00235-21. [Abstract]
- ACS Pharmacol Transl Sci. 2020 Oct 14;3(6):1278-1292. [Abstract]
- Pathogens. 2026 Mar 18;15(3):324. [Abstract]
- Viruses. 2025 Dec 27.
- Viruses. 2025 Jul 23;17(8):1028. [Abstract]
- Viruses. 2024 Apr 29, 16(5), 708.
- Viruses. 2022 Sep 12;14(9):2017. [Abstract]
- Viruses. 2022 Jun 23;14(7):1369. [Abstract]
- Viruses. 2022 Feb 8;14(2):353. [Abstract]
- Viruses. 2021 Apr 2;13(4):610. [Abstract]
- Viruses. 2021 Mar 26;13(4):558. [Abstract]
- Viruses. 2021 Feb 9;13(2):271. [Abstract]
- Viruses. 2020 Dec 5;12(12):1394. [Abstract]
- J Gen Virol. 2020 Sep;101(9):925-940. [Abstract]
- Viruses. 2020 Jun 10;12(6):628. [Abstract]
- J Med Virol. 2025 Nov;97(11):e70713. [Abstract]
- J Med Virol. 2021 Mar;93(3):1403-1408. [Abstract]
- Anim Cells Syst. 2026 Apr 20;30(1):381-393. [Abstract]
- Virus Res. 2026 Jan:363:199678. [Abstract]
- IUBMB Life. 2022 Jan;74(1):93-100. [Abstract]
- J Appl Toxicol. 2022 Oct;42(10):1688-1700. [Abstract]
- PLoS One. 2025 Feb 5;20(2):e0316952. [Abstract]
- Biosaf Health. 2024 Sep 3;6(5):270-278. [Abstract]
- PLoS One. 2022 Nov 10;17(11):e0276751. [Abstract]
- Chem Zvesti. 2021;75(9):4669-4685. [Abstract]
- New J Chem. 2020 Oct 12.
- J Chromatogr B Analyt Technol Biomed Life Sci. 2021 May 1:1171:122641. [Abstract]
- J Hum Lact. 2022 May;38(2):248-251. [Abstract]
- bioRxiv. 2026 Jun 13.
- bioRxiv. 2026 May 15.
- bioRxiv. 2026 May 12:2026.05.12.724615. [Abstract]
- bioRxiv. 2026 Mar 24.
- SSRN. 2026 Mar 7.
- Biomed Pharmacother. 2026 Feb 2:196:119076. [Abstract]
- Michigan State University. 2025.
- bioRxiv. 2025 Oct 8.
- bioRxiv. 2025 Oct 20.
- SSRN. 2025 Sep 19.
- Patent. US20250268848A1.
- Patent. US20250250647A1.
- NAR Mol Med. 2025 Aug 11;2(3):ugaf029. [Abstract]
- Biomed Pharmacother. 2025 Jun:187:118104. [Abstract]
- bioRxiv. 2025 Jun 23.
- SSRN. 2025 May 30.
- Res Sq. 2025 Apr 20.
- Patent. US20250123269A1.
- bioRxiv. 2025 February 28.
- Patent. US20250049841A1.
- Patent. US20240352022A1
- bioRxiv. 2025 Jan 10:2025.01.10.632212. [Abstract]
- Patent. US20240390328A1.
- medRxiv. 2024 Jun 18:2024.06.14.24308523. [Abstract]
- bioRxiv. 2024 Mar 1.
- bioRxiv. 2024 Feb 9:2023.11.20.567873. [Abstract]
- Preprints. 2024 Feb 19.
- Preprints. 2024 Jan 3.
- SSRN. 2024 Jan 26.
- bioRxiv. 2024 Jan 6.
- Patent. US20230312571A1.
- University of California. 2023 Jun.
- Patent. US20230123135A1.
- Research Square Preprint. 2023 Apr 5.
- SSRN. 2023 Mar 30.
- bioRxiv. 2023 Mar 9.
- bioRxiv. 2023 Feb 24.
- Utah State University. 2023 Feb 1.
- Ruprecht Karls University. 2023.
- Patent. US20220389050A1.
- Patent. US20220380769A1.
- Patent. US20220339132A1.
- Patent. US20220339140A1.
- Patent. US20220288080A1.
- Preprints. 2022, 2022070375.
- J Mol Liq. 2022 May 1:353:118775. [Abstract]
- Preprints. 2022, 2022050381.
- Curr Res Virol Sci. 2022;3:100019. [Abstract]
- bioRxiv. January 03, 2022.
- bioRxiv. January 10, 2022.
- University of Texas. 2021.
- Eur Rev Med Pharmacol Sci. 2021 Dec;25(1 Suppl):81-89. [Abstract]
- Patent. US20210379058A1.
- Patent. US20210346411A1.
- Phytomed Plus. 2021 Nov;1(4):100058. [Abstract]
- Research Square Preprint. 2021 Aug.
- Patent. US20210220377A1.
- bioRxiv. 2021 Aug 10:2021.08.06.455494. [Abstract]
- bioRxiv. 2021 Mar 25:2021.03.25.437060. [Abstract]
- Res Sq. 2020 Oct 7:rs.3.rs-86169. [Abstract]
- Universidade de São Paulo. 2020 Sep.
- ChemRxiv. 2020 Jun.
- bioRxiv. 2020 May.
- F1000Res. 2020 May.
- bioRxiv. 2020 May.
- bioRxiv. 2020 Apr.
- bioRxiv. 2020 Apr.
- bioRxiv. 2020 Mar.
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
IF
-
IF
-
IF
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Remdesivir maleate inhibits MHV replication with an IC50 of 1.1 μM in infected delayed brain tumor (DBT) cells with MHV[1].
Remdesivir maleate (2 μM, 2 h preinfection and 2 h postinfection) shows maximal inhibition in infected cells with MHV[1].
Remdesivir maleate (1-10 μM, 24-72 h) decreases SARS-CoV and MERS-CoV viral titer in HAE cells[1].
Remdesivir maleate inhibits 2019-nCoV with an EC50 of 0.77 μM and CC50 >100 μM[2].
Remdesivir maleate shows antiviral activity with EC50 values of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Remdesivir maleate (10 mg/kg, i.v.) shows 100% protection against Ebola virus infection in nonhuman primate (NHP) models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2250110-53-1
-
Molecular Weight 718.65
-
Formula C31H39N6O12P
-
SMILES
OC(/C=C\C(O)=O)=O.N#C[C@@]1(C2=CC=C3N2N=CN=C3N)O[C@@H]([C@H]([C@H]1O)O)COP(OC4=CC=CC=C4)(N[C@@H](C)C(OCC(CC)CC)=O)=O
-
Synonyms
GS-5734 maleate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (226)
-
Journal Impact Factor
-
Most Recent
-
N Engl J Med
2023 Jan 5;388(1):89-91. PMID: 36476720 -
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Signal Transduct Target Ther
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. [Abstract]2021 Apr 24;6(1):165. PMID: 33895786 -
Signal Transduct Target Ther
Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. [Abstract]2021 Feb 4;6(1):51. PMID: 33542181 -
Nature
2021 May;593(7859):418-423. PMID: 33727703 -
Nature
2020 Jun;582(7813):561-565. PMID: 32365353
Remdesivir maleate purchased from MedChemExpress. Usage Cited in: Nature. 2020 Jun;582(7813):561-565. [Abstract]
Remdesivir treatment showing the use of synSARS-CoV-2-GFP. Vero E6 cells were infected with synSARS-CoV-2-GFP (MOI = 0.01) and treated with 0.2 μM, 2 μM or without Remdesivir. DMSO was used as treatment in cells that were not incubated with Remdesivir. Mock, uninfected cells. At 48 h after infection, cells were analysed by fluorescence microscopy to detect GFP expression (left) and cell-culture supernatants were collected and titrated by TCID50 assay (right).
-
Science
2021 Nov 26;374(6571):1099-1106. PMID: 34648371
Remdesivir maleate purchased from MedChemExpress. Usage Cited in: Science. 2021 Nov 26;374(6571):1099-1106. [Abstract]
Time course measurements of cell viability of Huh-7.5 cells electroporated with WT or Nsp1 K164A/H165A double mutant (Nsp1mut) Gluc replicon RNA. Cells were seeded with 100 nM Remdesivir or vehicle and were washed in phosphate-buffered saline 24 hours before each respective time-point collection. Mock-electroporated cells were used as controls for post-electroporation cell viability. The dashed line indicates the limit of detection. N = 4. Error bars indicate SD.
-
Science
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. [Abstract]2020 Jun 26;368(6498):1499-1504. PMID: 32358203 -
Cell Res
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. [Abstract]2020 Mar;30(3):269-271. PMID: 32020029
Remdesivir maleate purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Mar;30(3):269-271. [Abstract]
Remdesivir (0.21-5.56 μM) inhibits virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2.
-
Nat Cell Biol
A placental model of SARS-CoV-2 infection reveals ACE2-dependent susceptibility and differentiation impairment in syncytiotrophoblasts. [Abstract]2023 Aug;25(8):1223-1234. PMID: 37443288
Remdesivir maleate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2023 Aug;25(8):1223-1234. [Abstract]
Virus titre expressed in ‘Luminescence relative light units (RLU)’ and genome copy analysis of d5 infected STs ± antiviral drug treatment (Rem = Remdesivir (1 μM; 3 h); NHC = Molnupiravir).
-
J Extracell Vesicles
Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. [Abstract]2022 Jan;11(1):e12179. PMID: 34982509 -
Sci Bull
Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2. [Abstract]2021 May 15;66(9):925-936. PMID: 33318880
Remdesivir maleate purchased from MedChemExpress. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936. [Abstract]
Immunofluorescence of intracellular viral N protein. Intracellular expression of N protein was assessed by staining of infected Vero E6 cells with the polyclonal anti-N antibody (1:1000 dilution, green). Nuclei were stained with DAPI. CPE was shown in bright field. The results showed that Remdesivir (6.25 µmol/L) significantly inhibited N protein expression.
-
Nat Microbiol
2024 May;9(5):1189-1206. PMID: 38548923 -
Nat Commun
2026 Mar 17;17(1):4058. PMID: 41844638 -
Nat Commun
2023 Jul 15;14(1):4231. PMID: 37454219 -
Nat Commun
2023 Jul 4;14(1):3952. PMID: 37402789 -
Nat Commun
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. [Abstract]2021 Nov 5;12(1):6415. PMID: 34741049 -
Nat Commun
2021 Oct 4;12(1):5811. PMID: 34608151 -
Nat Commun
Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics. [Abstract]2021 Aug 9;12(1):4887. PMID: 34373446 -
Cell Discov
Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes. [Abstract]2022 Sep 9;8(1):89. PMID: 36085197 -
Redox Biol
2021 Sep:45:102041. PMID: 34146958 -
Sci Transl Med
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. [Abstract]2023 Jan 18;15(679):eabq4064. PMID: 36327352 -
Nucleic Acids Res
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390 -
Acta Pharm Sin B
Insights into SARS-CoV-2 replication control via targeting the host hijacking function of NSP12. [Abstract]2026 Jul;16(7):4410-4425. PMID: 42453420 -
Acta Pharm Sin B
2024 Sep;14(9):4028-4044. PMID: 39309487 -
Acta Pharm Sin B
Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2. [Abstract]2021 Sep;11(9):2850-2858. PMID: 33723501 -
MedComm (2020)
2025 Aug 31;6(9):e70353. PMID: 40900808 -
Cell Rep Med
Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery. [Abstract]2026 Mar 9:102646. PMID: 41806841 -
Biomaterials
3D-printed airway model as a platform for SARS-CoV-2 infection and antiviral drug testing. [Abstract]2024 Dec:311:122689. PMID: 38944967 -
Biomaterials
Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection. [Abstract]2022 Apr:283:121460. PMID: 35286852 -
J Control Release
Intranasal liposomal remdesivir induces SARS-CoV-2 clearance in K18-hACE2 mice and ensures survival. [Abstract]2025 Jan 22:379:558-573. PMID: 39837387 -
Int J Biol Sci
NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence via the induction of ASCT2. [Abstract]2020 Oct 16;16(16):3100-3115. PMID: 33162818 -
EBioMedicine
Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids. [Abstract]2022 Jul:81:104132. PMID: 35779493 -
Arch Toxicol
The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro. [Abstract]2022 Aug;96(8):2341-2360. PMID: 35579693 -
Acta Pharmacol Sin
Carrimycin exhibited broad spectrum inhibitory activities against coronaviruses replication through down-regulating host factor TMEM41B. [Abstract]2025 Jul;46(7):2006-2015. PMID: 40374896 -
Cell Chem Biol
Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses. [Abstract]2022 Jul 21;29(7):1113-1125.e6. PMID: 35728599 -
Int J Nanomedicine
Antiviral Lipid Nanocarrier Loaded with Remdesivir Effective Against SARS-CoV-2 in vitro Model. [Abstract]2023 Mar 27:18:1561-1575. PMID: 37007987 -
Int J Biol Macromol
Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches. [Abstract]2021 Jan 31:168:474-485. PMID: 33290767 -
Microbiol Res
Transcriptome dynamics of the BHK21 cell line in response to human coronavirus OC43 infection. [Abstract]2024 Aug:285:127750. PMID: 38761489 -
Phytother Res
Ouratein D, a Biflavanone From Ouratea spectabilis, Alleviates Betacoronavirus Infection by Mitigating Inflammation, Lung Damage and Viral Replication. [Abstract]2025 Mar 18. PMID: 40099709 -
Cell Rep
An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo. [Abstract]2024 Nov 5;43(11):114929. PMID: 39504242 -
Cell Rep
Contribution of autophagy machinery factors to HCV and SARS-CoV-2 replication organelle formation. [Abstract]2021 Nov 23;37(8):110049. PMID: 34788596 -
Cell Rep
Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. [Abstract]2021 Apr 6;35(1):108959. PMID: 33811811 -
Genes Dev
2021 Jul 1;35(13-14):1005-1019. PMID: 34168039 -
J Med Chem
2025 Sep 25;68(18):19076-19106. PMID: 40910582 -
J Med Chem
Differential Bioactivation Profiles of Different GS-441524 Prodrugs in Cell and Mouse Models: ProTide Prodrugs with High Cell Permeability and Susceptibility to Cathepsin A Are More Efficient in Delivering Antiviral Active Metabolites to the Lung. [Abstract]2024 May 9;67(9):7470-7486. PMID: 38690769 -
Emerg Microbes Infect
A novel transcription and replication-competent virus-like particles system modelling the Nipah virus life cycle. [Abstract]2024 Dec;13(1):2368217. PMID: 38865205 -
Fundam Res
2023 Apr 7;5(6):2975-2982. PMID: 41467005 -
Emerg Microbes Infect
Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. [Abstract]2021 Dec;10(1):291-304. PMID: 33538646 -
Emerg Microbes Infect
The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. [Abstract]2021 Dec;10(1):317-330. PMID: 33560940 -
Pharmaceutics
Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia. [Abstract]2024 Sep 27;16(10):1262. PMID: 39458594 -
Pharmaceutics
Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection. [Abstract]2021 Oct 11;13(10):1656. PMID: 34683949 -
J Ethnopharmacol
Mechanistic insights into the dual anti-COVID-19 and anti-inflammatory actions of Zhengqi tablets. [Abstract]2025 Aug 29:352:120249. PMID: 40619041 -
J Ethnopharmacol
Anticoronavirus activity of rhizome of Dryopteris crassirhizoma via multistage targeting of virus entry and viral proteases, Mpro and PLpro. [Abstract]2024 Oct 28:333:118490. PMID: 38925321 -
Eur J Med Chem
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2. [Abstract]2021 Nov 15:224:113683. PMID: 34273661 -
Mol Syst Biol
2021 Feb;17(2):e10188. PMID: 33590968 -
Cell Biosci
Targeting stress induction of GRP78 by cardiac glycoside oleandrin dually suppresses cancer and COVID-19. [Abstract]2024 Sep 6;14(1):115. PMID: 39238058 -
Biomed J
Perilla (Perilla frutescens) leaf extract inhibits SARS-CoV-2 via direct virus inactivation. [Abstract]2021 Jun;44(3):293-303. PMID: 34119448 -
Biosensors (Basel)
Aptamer-Gated Mesoporous Silica Nanoparticles for N Protein Triggered Release of Remdesivir and Treatment of Novel Coronavirus (2019-nCoV). [Abstract]2022 Nov 1;12(11):950. PMID: 36354459 -
Bioeng Transl Med
IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development. [Abstract]2020 Dec 1;6(1):e10196. PMID: 33532594 -
J Cell Biol
SARS-CoV-2 NSP3/4 control formation of replication organelle and recruitment of RNA polymerase NSP12. [Abstract]2025 Mar 3;224(3):e202306101. PMID: 39737877 -
J Neuroimmune Pharmacol
Differential Cytokine Responses of APOE3 and APOE4 Blood-brain Barrier Cell Types to SARS-CoV-2 Spike Proteins. [Abstract]2024 May 21;19(1):22. PMID: 38771543 -
-
Commun Biol
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. [Abstract]2022 Feb 22;5(1):154. PMID: 35194144 -
Eur J Pharmacol
Iguratimod, a promising therapeutic agent for COVID-19 that attenuates excessive inflammation in mouse models. [Abstract]2025 Jun 5:996:177537. PMID: 40147575 -
Pharmaceuticals (Basel)
2020 Apr 10;13(4):65. PMID: 32290348 -
Int J Mol Sci
Electrophysiological and Molecular Features of Remdesivir-Induced Cardiac Toxicity in Male and Female Guinea Pigs. [Abstract]2026 Apr 21;27(8):3685. PMID: 42074328 -
Stem Cell Reports
Parallel use of human stem cell lung and heart models provide insights for SARS-CoV-2 treatment. [Abstract]2023 Jun 13;18(6):1308-1324. PMID: 37315523 -
Biomolecules
In Vitro Anti-SARS-CoV-2 Activity of Selected Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study. [Abstract]2021 Dec 10;11(12):1858. PMID: 34944502 -
Int J Mol Sci
Pseudo-Dipeptide Bearing α,α-Difluoromethyl Ketone Moiety as Electrophilic Warhead with Activity against Coronaviruses. [Abstract]2021 Jan 30;22(3):1398. PMID: 33573283 -
Front Cell Infect Microbiol
Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection. [Abstract]2021 Jul 30:11:700502. PMID: 34395311 -
mBio
A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance. [Abstract]2023 Aug 31;14(4):e0106023. PMID: 37338298 -
mBio
Strategy To Assess Zoonotic Potential Reveals Low Risk Posed by SARS-Related Coronaviruses from Bat and Pangolin. [Abstract]2023 Apr 25;14(2):e0328522. PMID: 36786573 -
Front Pharmacol
Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of I K(M) or I K(DR) and in the Stimulation of I MEP. [Abstract]2020 Jul 21;11:1091. PMID: 32792942 -
ACS Omega
Antiviral Activity of Dendritic Heparan Sulfate Mimetics against Respiratory Syncytial Virus and Herpes Simplex Virus‑1. [Abstract]2026 Apr 30;11(18):26533-26543. PMID: 42146132 -
ACS Omega
Enzymatic Glucosylation Enhances the Solubility of Niclosamide but Abrogates Its Therapeutic Efficacy. [Abstract]2026 Jan 26;11(5):8667-8677. PMID: 41696203 -
Molecules
Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity. [Abstract]2022 Dec 12;27(24):8829. PMID: 36557962 -
Molecules
Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E). [Abstract]2020 May 17;25(10):2343. PMID: 32429580 -
Sci Rep
Glycan-binding properties of SARS-CoV-2 spike proteins: interactions with aminoglycoside antibiotics. [Abstract]2026 Mar 9. PMID: 41803230 -
Sci Rep
High-throughput in vitro screening and in silico analysis for Zika virus inhibitor identification. [Abstract]2025 Nov 27. PMID: 41310171 -
Sci Rep
2025 Aug 2;15(1):28197. PMID: 40750837 -
Sci Rep
In silico screening and experimental validation identify riboflavin as an RNA-targeted antiviral against SARS-CoV-2. [Abstract]2025 Aug 22;15(1):30935. PMID: 40846756 -
Sci Rep
Construction and validation of a cell based reporter assay for identifying inhibitors of SARS coronavirus 2 RNA dependent RNA polymerase activity. [Abstract]2025 May 26;15(1):18443. PMID: 40419748 -
Sci Rep
2023 Nov 17;13(1):20178. PMID: 37978223 -
Sci Rep
Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models. [Abstract]2021 Dec 6;11(1):23465. PMID: 34873274 -
PLoS Pathog
In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. [Abstract]2021 Sep 17;17(9):e1009929. PMID: 34534263 -
Sci Rep
MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2. [Abstract]2021 Mar 8;11(1):5376. PMID: 33686154 -
Sci Rep
2021 Mar 8;11(1):5433. PMID: 33686143 -
Sci Rep
Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2. [Abstract]2021 Jan 12;11(1):821. PMID: 33436985 -
Sci Rep
Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19. [Abstract]2020 Oct 1;10(1):16200. PMID: 33004837 -
Comput Struct Biotechnol J
2022:20:5193-5202. PMID: 36059866 -
Virol Sin
Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies. [Abstract]2025 Mar 25:S1995-820X(25)00031-8. PMID: 40147635 -
Virol Sin
Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro. [Abstract]2023 Oct;38(5):778-786. PMID: 37406816 -
Microorganisms
The New Generation h DHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses. [Abstract]2021 Aug 14;9(8):1731. PMID: 34442810 -
Microorganisms
Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors. [Abstract]2021 Mar 31;9(4):734. PMID: 33807492 -
Microorganisms
Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. [Abstract]2020 Nov 26;8(12):1872. PMID: 33256227 -
Int J Infect Dis
Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients. [Abstract]2024 Sep:146:107134. PMID: 38944411 -
ACS Infect Dis
Single-Molecule Assay Reveals Binding Dynamics of SARS-CoV-2 Polymerase Components and Provides a New Tool to Distinguish Polymerase Inhibitors. [Abstract]2025 Jun 13;11(6):1518-1527. PMID: 40465830 -
iScience
Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells. [Abstract]2021 Dec 17;24(12):103412. PMID: 34786537 -
Biomedicines
In Vitro Replication Inhibitory Activity of Xanthorrhizol against Severe Acute Respiratory Syndrome Coronavirus 2. [Abstract]2021 Nov 19;9(11):1725. PMID: 34829954 -
iScience
5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2. [Abstract]2021 Oct 22;24(10):103120. PMID: 34541466 -
Biomedicines
SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System. [Abstract]2021 Aug 11;9(8):996. PMID: 34440200 -
J Neural Transm (Vienna)
Remdesivir shifts circadian rhythmicity to eveningness; similar to the most prevalent chronotype in ADHD. [Abstract]2021 Jul;128(7):1159-1168. PMID: 34273024 -
Antiviral Res
Broad-spectrum antiviral screening reveals pyrimidine biosynthesis as a target for inhibiting measles virus replication. [Abstract]2026 Jun:250:106413. PMID: 41967510 -
Antiviral Res
Genetic determinants of efficacy of antiviral drugs revealed by genome-wide CRISPR screens. [Abstract]2025 Dec:244:106309. PMID: 41260510 -
Antiviral Res
Dexamethasone treatment does not alter mortality but reduces pulmonary pathology in Nipah virus-infected Syrian hamsters. [Abstract]2025 Oct:242:106263. PMID: 40835030 -
Antiviral Res
2025 Apr:236:106114. PMID: 39954869 -
Antiviral Res
Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A. [Abstract]2024 May:225:105856. PMID: 38447646 -
Antiviral Res
PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding. [Abstract]2023 Sep:217:105700. PMID: 37562608 -
Antiviral Res
Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors. [Abstract]2023 Aug:216:105671. PMID: 37451629 -
Antiviral Res
Development of a novel minigenome and recombinant VSV expressing Seoul hantavirus glycoprotein-based assays to identify anti-hantavirus therapeutics. [Abstract]2023 Jun:214:105619. PMID: 37142192 -
Antiviral Res
Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2. [Abstract]2023 Jun:214:105606. PMID: 37076089 -
Antiviral Res
Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters. [Abstract]2022 Aug:204:105365. PMID: 35732228 -
Clin Transl Sci
Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS-441524 in patients with COVID-19: A limited case series. [Abstract]2022 Mar;15(3):732-740. PMID: 34761554 -
Clin Transl Sci
Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. [Abstract]2022 Feb;15(2):501-513. PMID: 34719115 -
Mol Divers
2021 Aug;25(3):1839-1854. PMID: 33389560 -
Antiviral Res
2021 Jul:191:105089. PMID: 34010661 -
Antiviral Res
Advancing Marburg virus antiviral screening: Optimization of a novel T7 polymerase-independent minigenome system. [Abstract]2021 Jan:185:104977. PMID: 33220335 -
Antiviral Res
Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. [Abstract]2020 Dec:184:104955. PMID: 33091434 -
Antiviral Res
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. [Abstract]2020 Jun:178:104786. PMID: 32251767 -
Antimicrob Agents Chemother
Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice. [Abstract]2024 Oct 8;68(10):e0103924. PMID: 39240093 -
Antimicrob Agents Chemother
Inhibition of endocytic uptake of severe acute respiratory syndrome coronavirus 2 and endo-lysosomal acidification by diphenoxylate. [Abstract]2024 Jun 5;68(6):e0034124. PMID: 38742905 -
Antimicrob Agents Chemother
Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals. [Abstract]2023 Apr 18;67(4):e0170322. PMID: 36975844 -
Antimicrob Agents Chemother
2020 Jun 23;64(7):e00819-20. PMID: 32366720 -
Microbiol Spectr
Host-directed antiviral strategy targeting prohibitins: Mel56 suppresses influenza A virus and severe acute respiratory syndrome coronavirus 2 via modulation of antioxidant pathways and mitochondrial function. [Abstract]2026 May 15:e0309325. PMID: 42138434 -
J Virol
2024 Feb 20;98(2):e0121623. PMID: 38236006 -
J Antimicrob Chemother
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo. [Abstract]2023 Apr 3;78(4):946-952. PMID: 36760083 -
J Virol
Comparison of Zaire and Bundibugyo Ebolavirus Polymerase Complexes and Susceptibility to Antivirals through a Newly Developed Bundibugyo Minigenome System. [Abstract]2021 Sep 27;95(20):e0064321. PMID: 34379503 -
Virol J
Mycophenolate mofetil exerts broad-spectrum antiviral activity against coronaviruses including SARS-CoV-2. [Abstract]2025 Mar 4;22(1):56. PMID: 40038695 -
Virol J
2023 Jan 31;20(1):18. PMID: 36721152 -
mSphere
2021 May 5;6(3):e00235-21. PMID: 33952663 -
ACS Pharmacol Transl Sci
2020 Oct 14;3(6):1278-1292. PMID: 33330842 -
Pathogens
Antiviral Activity of Pyrazolopyrimidine and Triazolopyrimidine Derivatives Against SARS-CoV-2 In Vitro: Identifying PZP25 as a Promising Scaffold. [Abstract]2026 Mar 18;15(3):324. PMID: 41901777 -
-
Viruses
4-Hydroxychalcone Inhibits Human Coronavirus HCoV-OC43 by Targeting EGFR/AKT/ERK1/2 Signaling Pathway. [Abstract]2025 Jul 23;17(8):1028. PMID: 40872743 -
-
Viruses
Molecular Analyses of Clinical Isolates and Recombinant SARS-CoV-2 Carrying B.1 and B.1.617.2 Spike Mutations Suggest a Potential Role of Non-Spike Mutations in Infection Kinetics. [Abstract]2022 Sep 12;14(9):2017. PMID: 36146823 -
Viruses
A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants. [Abstract]2022 Jun 23;14(7):1369. PMID: 35891350 -
Viruses
Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19. [Abstract]2022 Feb 8;14(2):353. PMID: 35215943 -
Viruses
Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. [Abstract]2021 Apr 2;13(4):610. PMID: 33918368 -
Viruses
In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. [Abstract]2021 Mar 26;13(4):558. PMID: 33810356 -
Viruses
2021 Feb 9;13(2):271. PMID: 33572467 -
Viruses
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro. [Abstract]2020 Dec 5;12(12):1394. PMID: 33291455 -
J Gen Virol
SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. [Abstract]2020 Sep;101(9):925-940. PMID: 32568027 -
Viruses
Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]2020 Jun 10;12(6):628. PMID: 32532085 -
J Med Virol
Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection. [Abstract]2025 Nov;97(11):e70713. PMID: 41263140 -
J Med Virol
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. [Abstract]2021 Mar;93(3):1403-1408. PMID: 32767684 -
Anim Cells Syst
CD47-mediated purification of human ventricular cardiomyocytes derived from pluripotent stem cells. [Abstract]2026 Apr 20;30(1):381-393. PMID: 42027966 -
Virus Res
2026 Jan:363:199678. PMID: 41419169 -
IUBMB Life
Endoplasmic reticulum stress and NF-kB activation in SARS-CoV-2 infected cells and their response to antiviral therapy. [Abstract]2022 Jan;74(1):93-100. PMID: 34390301 -
J Appl Toxicol
The mechanism and effects of remdesivir-induced developmental toxicity in zebrafish: Blood flow dysfunction and behavioral alterations. [Abstract]2022 Oct;42(10):1688-1700. PMID: 35560222 -
PLoS One
Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection. [Abstract]2025 Feb 5;20(2):e0316952. PMID: 39908288 -
Biosaf Health
2024 Sep 3;6(5):270-278. PMID: 40078736 -
PLoS One
Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients. [Abstract]2022 Nov 10;17(11):e0276751. PMID: 36355808 -
Chem Zvesti
RETRACTED ARTICLE: Discovery of (E)- N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug. [Abstract]2021;75(9):4669-4685. PMID: 34025012 -
-
J Chromatogr B Analyt Technol Biomed Life Sci
Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma. [Abstract]2021 May 1:1171:122641. PMID: 33756448 -
J Hum Lact
2022 May;38(2):248-251. PMID: 35189734 -
-
-
bioRxiv
Recovery of proofreading-impaired SARS-CoV-2 reveals a mutator phenotype and an ExoN activity threshold for viability. [Abstract]2026 May 12:2026.05.12.724615. PMID: 42182104 -
-
-
Biomed Pharmacother
MG-101, a cysteine protease inhibitor identified through high-throughput screening, exhibits in vivo efficacy and synergy with remdesivir against SARS-CoV-2. [Abstract]2026 Feb 2:196:119076. PMID: 41633253 -
-
-
-
-
-
-
NAR Mol Med
Mechanism and spectrum of inhibition of viral polymerases by 2'-deoxy-2'-β-fluoro-4'-azidocytidine or azvudine. [Abstract]2025 Aug 11;2(3):ugaf029. PMID: 40900943 -
Biomed Pharmacother
Drug repositioning: Identification of potent inhibitors of NS3 protease and NS5 RdRp for control of DENV infection. [Abstract]2025 Jun:187:118104. PMID: 40300391 -
-
-
-
-
-
-
-
bioRxiv
Single-molecule assay reveals the impact of composition, RNA duplex, and inhibitors on the binding dynamics of SARS-CoV-2 polymerase complex. [Abstract]2025 Jan 10:2025.01.10.632212. PMID: 39829757 -
-
medRxiv
Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections. [Abstract]2024 Jun 18:2024.06.14.24308523. PMID: 38946967 -
-
bioRxiv
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. [Abstract]2024 Feb 9:2023.11.20.567873. PMID: 38045308 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
J Mol Liq
Antiviral activities of 4H-chromen-4-one scaffold-containing flavonoids against SARS-CoV-2 using computational and in vitro approaches. [Abstract]2022 May 1:353:118775. PMID: 35194277 -
-
Curr Res Virol Sci
Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern. [Abstract]2022;3:100019. PMID: 35072124 -
-
-
-
Eur Rev Med Pharmacol Sci
In vitro and clinical studies on the efficacy of α-cyclodextrin and hydroxytyrosol against SARS-CoV-2 infection. [Abstract]2021 Dec;25(1 Suppl):81-89. PMID: 34890038 -
-
-
Phytomed Plus
The potential of BEN815 as an anti-inflammatory, antiviral and antioxidant agent for the treatment of COVID-19. [Abstract]2021 Nov;1(4):100058. PMID: 35403084 -
-
-
bioRxiv
Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524). [Abstract]2021 Aug 10:2021.08.06.455494. PMID: 34401879 -
bioRxiv
Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses. [Abstract]2021 Mar 25:2021.03.25.437060. PMID: 33791708 -
Res Sq
Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters. [Abstract]2020 Oct 7:rs.3.rs-86169. PMID: 33052331 -
-
-
-
-
-
-
-
Purity & Documentation
References
[1]. Agostini ML, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018 Mar 6;9(2). pii: e00221-18. [Content Brief]
[2]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. [Content Brief]
[3]. Hu H, et al. Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. J Med Chem. 2022 Sep 22;65(18):12044-12054. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)